Additional file 4: Figure S3. of Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Atsushi Aruga (3799726); Haruo Iguchi (3799699); Hideki Arima (3799705); Hidenobu Ishizaki (3799687); Hiroaki Nagano (282467); Hiroaki Tanaka (372008); Hiroko Takenouchi (3799711); Hiroto Matsui (3799714); Hiroyuki Furukawa (1612825); Kazuhiko Yoshimatsu (3799720); Kazuhiro Uesugi (3799693); Masaaki Oka (3799732); Michihisa Iida (3799690); Mitsuo Shimada (529476); Nobuaki Suzuki (191906); Shigefumi Yoshino (3799708); Shinsuke Kanekiyo (3799729); Shoichi Hazama (3549395); Takashi Hatori (3799723); Tetsuya Ikemoto (2666518); Tomio Ueno (3799717); Tomonobu Fujita (668183); Toshiyoshi Fujiwara (157767); Yasunobu Koki (3799702); Yoshitaro Shindo (3799696); Yusuke Nakamura (25445); Yutaka Kawakami (206073); Yuzo Umeda (762721)

Additional file 4: Figure S3. of Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Abstract

Frequency of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells. (a), (c) There were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells in the 46 patients before and after treatment. (b), (e) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 19) in the HLA-A*2402-matched group. (c), (f) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 15) in the HLA-A*2402-unmatched group. (TIF 60 kb

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/47015...

Last time updated on 12/02/2018